Korean Regulatory Overhaul To Cut Drug RnD, Approval Time
This article was originally published in SRA
The South Korean government has unveiled a series of regulatory reforms that are designed to step up the competitiveness of the pharma industry and supply drugs in time for public health emergencies.
You may also be interested in...
2016 has been full of shock and despair in South Korea’s political scene. But when it comes to the country’s biopharma policy, the year has seen fewer surprising or dramatic events.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.